** Shares in proton therapy machines maker Ion Beam
Applications IBAB.BR rise 5.5% after a funding round valued
its JV PanTera at 280 million euros ($254 million)
** The JV, focused on large-scale production of the
actinium-225 radioisotope to fight cancer, completed the
financing round of 93 million euros led by EQT Life Sciences
** Post-financing, IBA retains 31.3% participation in the JV
and will see a positive impact on profit of 23 million euros
from its stake revaluation
** ING says the news is positive on both "mechanically
financial" level, estimating a theoretical 2.27 euro/share
positive impact on IBA's share price, and on sentiment level
** It puts "on the radar screen of investors what could be
considered a JV that was a bit of a distant project, even if
attention about actinium had increased," ING says
** KBC expects funding to be sufficient to finalise the
isotope production facility with large-scale production by the
decade end - right on time for the expected uptick in demand
($1 = 0.9051 euros)
(Reporting by Piotr Lipinski)
((piotr.lipinski@tr.com))